SARcode Bioscience has raised $44 million in a series B private equity financing. Sofinnova Ventures led the financing, while Rho Ventures also participated in the fund raising.
The biopharmaceutical company’s existing investors, Alta Partners and Clarus Venture Partners, also took part in the deal. SARcode aims to use the proceeds to support further clinical development of SAR 1118, its lead compound for the treatment of dry eye syndrome.
Click here for the release from SARcode Biosciences.